Medtronic Stock (MDT) Slides Despite Corporate Re-Jig to Boost Ailing Valuation
Medtronic shares declined following a corporate reshuffle aimed at revitalizing its market valuation, now standing at $119 billion. Activist investor Elliott Investment Management has emerged as a significant shareholder, engaging in discussions to refocus the company on Core assets and growth strategies.
The medical technology firm is set to announce new board appointments and the creation of specialized committees to oversee mergers, acquisitions, and earnings growth initiatives. These moves come as Medtronic seeks to address its undervalued stock position and explore strategic opportunities in research and development.